Get access

Goal attainment after treatment of parkinsonian camptocormia with botulinum toxin

Authors

  • Urban M. Fietzek MD,

    1. Neurologisches Krankenhaus München, Schön Kliniken, Center for Parkinson's Disease and Movement Disorders, Parzivalplatz 4, Munich, Germany
    Search for more papers by this author
  • Frauke E. Schroeteler PT,

    1. Neurologisches Krankenhaus München, Schön Kliniken, Center for Parkinson's Disease and Movement Disorders, Parzivalplatz 4, Munich, Germany
    Search for more papers by this author
  • Andres O. Ceballos-Baumann MD

    Corresponding author
    1. Neurologisches Krankenhaus München, Schön Kliniken, Center for Parkinson's Disease and Movement Disorders, Parzivalplatz 4, Munich, Germany
    • Neurologisches Krankenhaus München, Schön Kliniken, Center for Parkinson's Disease and Movement Disorders, Parzivalplatz 4, Munich, Germany
    Search for more papers by this author

  • Potential conflict of interest: Merz Pharmaceutical GmbH, Frankfurt, Germany did not design the work, nor collect, analyze or interpret data, nor write any part of this report.

No abstract is available for this article.

Get access to the full text of this article

Ancillary